Page last updated: 2024-08-26

1-methyltryptophan and Neoplasms

1-methyltryptophan has been researched along with Neoplasms in 9 studies

Research

Studies (9)

Timeframe	Studies, this research(%)	All Research%
pre-1990	0 (0.00)	18.7374
1990's	0 (0.00)	18.2507
2000's	0 (0.00)	29.6817
2010's	5 (55.56)	24.3611
2020's	4 (44.44)	2.80

Authors

Authors	Studies
Bian, J; Li, Z; Qiu, X; Wang, J; Weng, T	1
Bian, J; Feng, X; Li, Z; Liao, D; Liu, D; Ping, A	1
Adams, J; Brincks, EL; Jaipuri, FA; Kumar, S; Link, C; Marcinowicz, A; Mautino, MR; Potturi, H; Vahanian, N; Van Allen, C; Waldo, JP; Zhuang, H	1
Chang, CH; Chiang, M; Ji, Y; Jiang, J; Khazaieli, M; Li, J; Liao, YP; Liu, Q; Liu, X; Mei, KC; Melano, B; Meng, H; Nel, AE; Telesca, D; Wang, X; Xia, T; Zhang, X	1
Hou, Z; Jiang, Y; Luan, Y; Ren, X; Wang, N; Zhou, Y	1
Brochez, L; Chevolet, I; Kruse, V	1
Smith, D; Yentz, S	1
Antonia, S; Dees, EC; Han, H; Harvey, RD; Ismail-Khan, R; Jackson, E; Link, C; Minton, S; Neuger, T; Soliman, HH; Sullivan, DM; Vahanian, NN	1
Antonia, SJ; Chiappori, AA; Han, HS; Ismail-Khan, R; Khambati, F; Link, C; Lush, R; Mautino, M; Minton, SE; Neuger, A; Noyes, D; Roberts, JD; Soliman, HH; Streicher, H; Sullivan, DM; Vahanian, NN	1

Reviews

4 review(s) available for 1-methyltryptophan and Neoplasms

Article	Year
Recent discovery of indoleamine-2,3-dioxygenase 1 inhibitors targeting cancer immunotherapy. European journal of medicinal chemistry, 2018, Jan-01, Volume: 143 Topics: Dose-Response Relationship, Drug; Drug Discovery; Enzyme Inhibitors; Humans; Immunotherapy; Indoleamine-Pyrrole 2,3,-Dioxygenase; Molecular Structure; Neoplasms; Structure-Activity Relationship	2018
Development of Indoleamine 2,3-Dioxygenase 1 Inhibitors for Cancer Therapy and Beyond: A Recent Perspective. Journal of medicinal chemistry, 2020, 12-24, Volume: 63, Issue:24 Topics: Binding Sites; Catalytic Domain; Drug Discovery; Enzyme Inhibitors; Humans; Indoleamine-Pyrrole 2,3,-Dioxygenase; Indoles; Molecular Docking Simulation; Neoplasms; Small Molecule Libraries	2020
The rationale of indoleamine 2,3-dioxygenase inhibition for cancer therapy. European journal of cancer (Oxford, England : 1990), 2017, Volume: 76 Topics: Antineoplastic Agents; Apoptosis; Cell Proliferation; Enzyme Inhibitors; Humans; Immune Tolerance; Indoleamine-Pyrrole 2,3,-Dioxygenase; Neoplasms; Oximes; Sulfonamides; T-Lymphocytes; Tryptophan	2017
Indoleamine 2,3-Dioxygenase (IDO) Inhibition as a Strategy to Augment Cancer Immunotherapy. BioDrugs : clinical immunotherapeutics, biopharmaceuticals and gene therapy, 2018, Volume: 32, Issue:4 Topics: Animals; Antineoplastic Agents; Clinical Trials as Topic; Enzyme Inhibitors; Humans; Immunotherapy; Indoleamine-Pyrrole 2,3,-Dioxygenase; Neoplasms; Oximes; Sulfonamides; Tryptophan; Tumor Microenvironment	2018

Trials

2 trial(s) available for 1-methyltryptophan and Neoplasms

Article	Year
A first in man phase I trial of the oral immunomodulator, indoximod, combined with docetaxel in patients with metastatic solid tumors. Oncotarget, 2014, Sep-30, Volume: 5, Issue:18 Topics: Administration, Intravenous; Administration, Oral; Adult; Antineoplastic Combined Chemotherapy Protocols; Docetaxel; Drug Administration Schedule; Drug Monitoring; Female; Florida; Humans; Immunologic Factors; Male; Maximum Tolerated Dose; Middle Aged; Neoplasm Metastasis; Neoplasms; Taxoids; Time Factors; Treatment Outcome; Tryptophan	2014
A phase I study of indoximod in patients with advanced malignancies. Oncotarget, 2016, Apr-19, Volume: 7, Issue:16 Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Dose-Response Relationship, Drug; Female; Humans; Indoleamine-Pyrrole 2,3,-Dioxygenase; Male; Maximum Tolerated Dose; Middle Aged; Neoplasms; Tryptophan; Young Adult	2016

Article

Year

A first in man phase I trial of the oral immunomodulator, indoximod, combined with docetaxel in patients with metastatic solid tumors.

Oncotarget, 2014, Sep-30, Volume: 5, Issue:18

Topics: Administration, Intravenous; Administration, Oral; Adult; Antineoplastic Combined Chemotherapy Protocols; Docetaxel; Drug Administration Schedule; Drug Monitoring; Female; Florida; Humans; Immunologic Factors; Male; Maximum Tolerated Dose; Middle Aged; Neoplasm Metastasis; Neoplasms; Taxoids; Time Factors; Treatment Outcome; Tryptophan

2014

A phase I study of indoximod in patients with advanced malignancies.

Oncotarget, 2016, Apr-19, Volume: 7, Issue:16

Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Dose-Response Relationship, Drug; Female; Humans; Indoleamine-Pyrrole 2,3,-Dioxygenase; Male; Maximum Tolerated Dose; Middle Aged; Neoplasms; Tryptophan; Young Adult

2016

Other Studies

3 other study(ies) available for 1-methyltryptophan and Neoplasms

Article	Year
Discovery of indoximod prodrugs and characterization of clinical candidate NLG802. European journal of medicinal chemistry, 2020, Jul-15, Volume: 198 Topics: Administration, Oral; Animals; Antineoplastic Agents; Apoptosis; Biological Availability; Cell Line, Tumor; Dose-Response Relationship, Drug; Drug Compounding; Drug Screening Assays, Antitumor; Haplorhini; Humans; Intestinal Absorption; Mice; Molecular Conformation; Neoplasms; Prodrugs; Rats; Tryptophan	2020
Liposomal Delivery of Mitoxantrone and a Cholesteryl Indoximod Prodrug Provides Effective Chemo-immunotherapy in Multiple Solid Tumors. ACS nano, 2020, 10-27, Volume: 14, Issue:10 Topics: Animals; Cell Line, Tumor; Immunotherapy; Liposomes; Mice; Mitoxantrone; Neoplasms; Prodrugs; Tryptophan	2020
Engineering a photosensitizer nanoplatform for amplified photodynamic immunotherapy via tumor microenvironment modulation. Nanoscale horizons, 2021, 02-01, Volume: 6, Issue:2 Topics: Animals; Antineoplastic Agents; Axitinib; Chlorophyllides; Dendritic Cells; Enzyme Inhibitors; Female; Immunity; Immunotherapy; Indoleamine-Pyrrole 2,3,-Dioxygenase; Light; Mice, Inbred C57BL; Nanoparticles; Neoplasms; Photochemotherapy; Photosensitizing Agents; Porphyrins; Protein Kinase Inhibitors; Tryptophan; Tumor Microenvironment	2021